Profil bibliographique

Shyam Kalavar

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

17Publications signalées

643Citations signalées

2Affiliations récentes

Les institutions déclarées

United States Food and Drug Administration Center for Devices and Radiological Health

Les domaines associés

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research

Les publications récentes

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S1 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

0 citations

Accès ouvert 2025 other OpenAlex

Data from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S3 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S2 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

0 citations

Accès ouvert 2025 article OpenAlex

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

William F. Maguire, Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng et autres

us (code pays fourni par la source)

2 citations Clinical Cancer Research

Accès ouvert 2024 article OpenAlex

US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations

Asma Dilawari, James Buturla, Christy Osgood, Xin Gao et autres

us (code pays fourni par la source)

46 citations Journal of Clinical Oncology

Accès ouvert 2024 article OpenAlex

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Brian L. Heiss, Elaine Chang, Xin Gao, Tien M. Truong et autres

us, jp, gb (code pays fourni par la source)

27 citations Journal of Clinical Oncology

Accès ouvert 2024 article OpenAlex

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer

Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman et autres

us (code pays fourni par la source)

48 citations Journal of Clinical Oncology

2023 article OpenAlex

FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Jianjin Xu, Chana Weinstock, Michael H. Brave et autres

us (code pays fourni par la source)

53 citations Journal of Clinical Oncology

Accès ouvert 2023 article OpenAlex

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman et autres

us (code pays fourni par la source)

117 citations Clinical Cancer Research

Accès ouvert 2023 article OpenAlex

FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

Luckson Mathieu, Erin Larkins, A. K. Sinha, Pallavi S. Mishra‐Kalyani et autres

us (code pays fourni par la source)

48 citations Clinical Cancer Research

2023 article OpenAlex

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng et autres

us (code pays fourni par la source)

52 citations Journal of Clinical Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.